CD19 MicroBeads, human

CD19 MicroBeads were developed for positive selection or depletion of CD19+ B cells from different cell sources such as human PBMCs, bone marrow, lymphoid tissues, or cell cultures.

qualityAssuranceSatisfaction
guaranteed
more »
Choose your product:

Related products for CD19 MicroBeads, human

Specifications for CD19 MicroBeads, human
Overview

CD19 MicroBeads were developed for positive selection or depletion of CD19+ B cells from different cell sources such as human PBMCs, bone marrow, lymphoid tissues, or cell cultures.

Detailed product information
Background information

As a B cell lineage marker, the CD19 antigen is expressed from the early pro-B cell stage to the B cell lymphoblast stage, but the expression is down-regulated upon B cell maturation to plasma cells. The CD19 antigen is further expressed on most malignant B cells and on a subset of follicular dendritic cells.

Downstream applications

Isolated CD19+ B cells were used for studies on immunoglobulin production, such as IgE synthesis1, 2 and secretion3, chemotaxis assays4, or mixed lymphocyte reactions. Positively selected CD19+ B cells were also used for molecular studies such as gene expression profiling.5 For the analysis of minimal residual diseases in B cell malignancies, enrichment of B cells increases the sensitivity of detection.6

Columns

For positive selection: MS, LS, XS, or autoMACS® Columns. For depletion: LD, D, or autoMACS Columns.

Product data and images for CD19 MicroBeads, human
Figure 1

CD19+ cells were isolated from human PBMCs using CD19 MicroBeads, an MS Column, and a MiniMACS™ Separator. Cells were fluorescently stained with CD19-PE and analyzed by flow cytometry. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Figure 2

Separation of CD19+ cells from PBMCs using CD19 MicroBeads, an MS Column, and a MiniMACS™ Separator.

Resources for CD19 MicroBeads, human
Citations for CD19 MicroBeads, human
Publications
  1. Zürcher, A. W. et al. (1995) IgE-producing hybridomas established after B-cell culture in the CD40 system. Immunol. Lett. 46: 49-57
  2. Aebischer, I. et al. (1994) Neuropeptides are potent modulators of human in vitro immunoglobulin E synthesis. Eur. J. Immunol. 24: 1908-1913
  3. Stämpfli, M. R. et al. (1994) Inhibition of human IgE synthesis by anti-IgE antibodies requires divalent recognition. Eur. J. Immunol. 24: 2161-2167
  4. Klein, U. et al. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 194: 1625-1638
  5. Schratzberger, P. et al. (1997) Differential chemotactic activities of sensory neuropeptides for human peripheral blood mononuclear cells. J Immunol 158: 3895-3901
  6. Pugh, R. E. et al. (1998) CD19 selection improves the sensitivity of B cell lymphoma detection. J. Hematother. 7: 159-168

You have previously chosen International as your location.
What do you want to do?